Filtered By:
Drug: Norvir
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 8 results found since Jan 2013.
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Publication date: Available online 3 May 2018 Source:The Lancet HIV Author(s): Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft Background Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted daru...
Source: The Lancet HIV - May 15, 2018 Category: Infectious Diseases Source Type: research
Relationship Between HIV Infection, Antiretroviral Therapy, Inflammatory Markers, and Cerebrovascular Endothelial Function Among Adults in Urban China
Conclusions: Cerebrovascular endothelial dysfunction associated with HIV infection may be most relevant for individuals with less traditional vascular risk, such as those with lower cholesterol. Further study of the impact of ART on cerebrovascular endothelial function is warranted to aid with ART selection in individuals at high cerebrovascular risk.
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - February 14, 2017 Category: Infectious Diseases Tags: Clinical Science Source Type: research
Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir.
Source: Drugs in R&D - July 10, 2018 Category: Drugs & Pharmacology Source Type: research
Protease inhibitors may increase risk of death in people with HIV and heart failure
Ritonavir-boosted protease inhibitors associated with doubled risk of hospital readmission and cardiovascular death Related items fromOnMedica Stroke rate higher in HIV patients £30 million to tackle antimicrobial resistance Single-dose malaria drug eliminates parasite from liver Ibuprofen not a safe alternative to antibiotics for uncomplicated UTIs Too few women take part in many CVD clinical trials
Source: OnMedica Latest News - July 24, 2018 Category: UK Health Source Type: news
Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir.
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
